Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

pCR Rate × Metformin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 148 Breast Neoplasms 39 Prostatic Neoplasms 31 Insulin Resistance 29 Obesity 22 Pancreatic Neoplasms 14 Neoplasms 14 Endometrial Neoplasms 14 Infertility 13 Colorectal Neoplasms 13 Carcinoma, Non-Small-Cell Lung 12 Anovulation 10 Lung Neoplasms 9 Neoplasm Metastasis 8 Hyperandrogenism 8 Glioblastoma 8 Diabetes Mellitus 8 Metabolic Syndrome 7 Melanoma 7 Squamous Cell Carcinoma of Head and Neck 6 Rectal Neoplasms 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Lymphoma, Large B-Cell, Diffuse 5 Brain Neoplasms 5 Adenocarcinoma 5 Weight Loss 4 Urinary Bladder Neoplasms 4 Ovarian Neoplasms 4 Mouth Neoplasms 4 Head and Neck Neoplasms 4

Interventions

Metformin 1 Epirubicin 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01929811 2022-04-06

NeoMET

Shanghai Jiao Tong University School of Medicine

Phase 2 Terminated

pCR Rate

Data powered by HemOnc (CC BY 4.0) Colophon ⚡